WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Palleon’s poster highlights recent preclinical data from in vitro and in vivo studies of the company’s most advanced therapeutic candidate, E-602 (formerly known as Bi-Sialidase). E-602 is part of the company’s novel cancer immunotherapy platform, EAGLE (Enzyme-Antibody Glycan-Ligand Editing), which utilizes engineered human sialidase to degrade immunosuppressive sialoglycans.

In addition to the poster presentation, Palleon will be hosting a hybrid (live and virtual) scientific symposium at SITC on November 11th featuring Palleon Scientific Co-Founder Carolyn Bertozzi, Ph.D., Scientific Advisor James Paulson, Ph.D., and Chief Medical Officer David Feltquate, M.D., Ph.D. The session will review the most recent state of the science of sialoglycan-mediated immune regulation and its potential relevance for immuno-oncology therapeutics. To learn more and register to attend, visit this link.

“We’re looking forward to sharing more about the development of our EAGLE platform and the lead program E-602, which we believe is a uniquely powerful way to reverse the immunosuppressive effect of cell-surface sialoglycans,” said Li Peng, Ph.D., Chief Scientific Officer. “These data will inform our upcoming Phase 1 clinical trial of E-602, as well as our growing pipeline of EAGLE therapeutic candidates in oncology.”